Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
F Shi, Y Liu, X Zhou, P Shen, R Xue, M Zhang - Drug Delivery, 2022 - Taylor & Francis
Human epidermal growth factor receptor 2 (HER2) regulates cell mitosis, proliferation, and
apoptosis. Trastuzumab is a HER2-targeted monoclonal antibody (mAB), which can prolong …
apoptosis. Trastuzumab is a HER2-targeted monoclonal antibody (mAB), which can prolong …
[HTML][HTML] mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation
Y Hu, F Chen, S Sun, L Xv, X Wang, M Wang… - Frontiers in …, 2024 - frontiersin.org
This study aimed to explore the efficacy and potential mechanisms of rechallenge therapy
with microtubule-targeting agents (MTAs) in patients with HER2-low metastatic breast …
with microtubule-targeting agents (MTAs) in patients with HER2-low metastatic breast …
Heterogeneity and utility of pharmaceutical company sharing of individual-participant data packages
Importance The pharmaceutical industry has made substantial investments in developing
processes for sharing individual-participant data (IPD) from clinical trials. However, the utility …
processes for sharing individual-participant data (IPD) from clinical trials. However, the utility …
[HTML][HTML] Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis
J Zhang, Y Yang, R Chen, S Chen, J Wang… - Annals of …, 2021 - ncbi.nlm.nih.gov
Background Trastuzumab emtansine (T-DM1) has been proved to have value and efficacy in
the treatment of advanced metastatic cancer, including in the adjuvant setting. However …
the treatment of advanced metastatic cancer, including in the adjuvant setting. However …
RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
P Wang, L Xia - BMC cancer, 2023 - Springer
Background RC48-antibody-drug conjugates (ADC) link humanized anti-HER2
immunoglobulin with monomethyl auristatin E (MMAE). Clinical trials suggest promising …
immunoglobulin with monomethyl auristatin E (MMAE). Clinical trials suggest promising …
[HTML][HTML] Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast …
R Wuerstlein, P Ellis, F Montemurro, AA Torres… - ESMO open, 2022 - Elsevier
Background KAMILLA is a single-arm safety study of trastuzumab emtansine (T-DM1) in
patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast …
patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast …
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy …
CS Huang, Y Yang, A Kwong, SC Chen… - Breast Cancer Research …, 2021 - Springer
Purpose In the KATHERINE study (NCT01772472), patients with HER2-positive early breast
cancer (EBC) and residual invasive disease after neoadjuvant chemotherapy plus HER2 …
cancer (EBC) and residual invasive disease after neoadjuvant chemotherapy plus HER2 …
[HTML][HTML] Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with …
Y Lan, J Zhao, F Zhao, J Li, X Li - Frontiers in Oncology, 2024 - ncbi.nlm.nih.gov
Breast cancer remains one of the predominant malignancies worldwide. In the context of
inoperable advanced or metastatic human epidermal growth factor receptor 2 (HER2) …
inoperable advanced or metastatic human epidermal growth factor receptor 2 (HER2) …
[HTML][HTML] Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus …
X Wang, W Li, Y Yin, Z Tong, Q Zhang… - Translational Breast …, 2023 - ncbi.nlm.nih.gov
Background The antibody-drug conjugate (ADCs) trastuzumab emtansine (T-DM1) is
approved for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast …
approved for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast …
Early thrombocytopenia predicts longer time‑to‑treatment discontinuation in trastuzumab emtansine treatment
Thrombocytopenia is a characteristic adverse event of trastuzumab emtansine (T‑DM1), one
of the essential treatment options for human epithelial growth factor receptor 2 (HER2) …
of the essential treatment options for human epithelial growth factor receptor 2 (HER2) …